Page last updated: 2024-08-22

lutetium and Paraganglioma, Gangliocytic

lutetium has been researched along with Paraganglioma, Gangliocytic in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Adjogatse, D; Black, JR; Pinato, DJ; Ramaswami, R; Sharma, R; Tan, TM	1
Bakker, WH; de Herder, WW; Feelders, RA; Kooij, PP; Krenning, EP; Kwekkeboom, DJ; van Essen, M; Wolbers, JG	1
Forrer, F; Maecke, HR; Mueller-Brand, J; Riedweg, I	1

Trials

1 trial(s) available for lutetium and Paraganglioma, Gangliocytic

Article	Year
Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2008, Volume: 52, Issue:4 Topics: Adult; Female; Humans; Lutetium; Male; Middle Aged; Neoplasm Staging; Octreotide; Paraganglioma; Pheochromocytoma; Staining and Labeling; Yttrium Radioisotopes	2008

Article

Year

Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma.

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2008, Volume: 52, Issue:4

Topics: Adult; Female; Humans; Lutetium; Male; Middle Aged; Neoplasm Staging; Octreotide; Paraganglioma; Pheochromocytoma; Staining and Labeling; Yttrium Radioisotopes

2008

Other Studies

2 other study(ies) available for lutetium and Paraganglioma, Gangliocytic

Article	Year
Peptide receptor radionuclide therapy for metastatic paragangliomas. Medical oncology (Northwood, London, England), 2016, Volume: 33, Issue:5 Topics: Adolescent; Adult; Female; Humans; Kaplan-Meier Estimate; Lutetium; Male; Middle Aged; Octreotide; Organometallic Compounds; Paraganglioma; Radioisotopes; Radiotherapy; Treatment Outcome	2016
Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2006, Volume: 47, Issue:10 Topics: Adult; Aged; Carcinoma, Small Cell; Eye Neoplasms; Female; Humans; Lung Neoplasms; Lutetium; Male; Melanoma; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Metastasis; Octreotide; Paraganglioma; Radioisotopes; Radiopharmaceuticals	2006

Article

Year

Peptide receptor radionuclide therapy for metastatic paragangliomas.

Medical oncology (Northwood, London, England), 2016, Volume: 33, Issue:5

Topics: Adolescent; Adult; Female; Humans; Kaplan-Meier Estimate; Lutetium; Male; Middle Aged; Octreotide; Organometallic Compounds; Paraganglioma; Radioisotopes; Radiotherapy; Treatment Outcome

2016

Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2006, Volume: 47, Issue:10

Topics: Adult; Aged; Carcinoma, Small Cell; Eye Neoplasms; Female; Humans; Lung Neoplasms; Lutetium; Male; Melanoma; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Metastasis; Octreotide; Paraganglioma; Radioisotopes; Radiopharmaceuticals

2006